Trial · NCT04707326
Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study
NCT04707326, Active not recruiting, Erasmus Medical Center; results first posted 2024-12-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study. Trials, record NCT04707326. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04707326
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study
- NCT number
- NCT04707326
- Status
- Active not recruiting
- Enrollment
- 2,040 participants, actual
- Lead sponsor
- Erasmus Medical Center
- Conditions
- Hiv
- Interventions
- Dolutegravir / Lamivudine Pill
- First posted
- 2021-01-13
- Last updated
- 2024-12-20
- Results first posted
- 2024-12-20
- Limitations and caveats
- All-Cause Mortality, Serious, or Other (non-serious) Adverse Events were collected during this study.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy On Treatment (OT) | 1 year | Proportion of subjects with treatment failure in the DTG/3TC versus 3-drug DTG containing cART group up to 1 year of follow up in the on treatment population |
| Primary | Efficacy Intention to Treat (ITT) | 1 year | Proportion of subjects with treatment failure in the DTG/3TC versus 3-drug DTG containing cART group up to 1 year of follow up in the intention to treat population. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Efficacy On Treatment (OT) | 1 year | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Efficacy Intention to Treat (ITT) | 1 year | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Efficacy On Treatment (OT) | DTG Based Switchers to DTG/3TC | 5 | Participants | ||
| Efficacy On Treatment (OT) | DTG Based Triple Drug cART | 5 | Participants | ||
| Efficacy On Treatment (OT) | Non-DTG Based Switchers to DTG/3TC | 2 | Participants | ||
| Efficacy On Treatment (OT) | Non-DTG Based Triple Drug cART | 4 | Participants | ||
| Efficacy Intention to Treat (ITT) | DTG Based Switchers to DTG/3TC | 34 | Participants | ||
| Efficacy Intention to Treat (ITT) | DTG Based Triple Drug cART | 89 | Participants | ||
| Efficacy Intention to Treat (ITT) | Non-DTG Based Switchers to DTG/3TC | 32 | Participants | ||
| Efficacy Intention to Treat (ITT) | Non-DTG Based Triple Drug cART | 73 | Participants |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | DTG Based Switchers to DTG/3TC | 390 | |
| Overall Study | STARTED | DTG Based Triple Drug cART | 780 | |
| Overall Study | STARTED | Non-DTG Based Switchers to DTG/3TC | 290 | |
| Overall Study | STARTED | Non-DTG Based Triple Drug cART | 580 | |
| Overall Study | COMPLETED | DTG Based Switchers to DTG/3TC | 390 | |
| Overall Study | COMPLETED | DTG Based Triple Drug cART | 780 | |
| Overall Study | COMPLETED | Non-DTG Based Switchers to DTG/3TC | 290 | |
| Overall Study | COMPLETED | Non-DTG Based Triple Drug cART | 580 | |
| Overall Study | NOT COMPLETED | DTG Based Switchers to DTG/3TC | 0 | |
| Overall Study | NOT COMPLETED | DTG Based Triple Drug cART | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | DTG Based Switchers to DTG/3TC | 0 | 390 |
| Total, all-cause mortality | DTG Based Triple Drug cART | 0 | 780 |
| Total, all-cause mortality | Non-DTG Based Switchers to DTG/3TC | 0 | 290 |
| Total, all-cause mortality | Non-DTG Based Triple Drug cART | 0 | 580 |
| Total, other adverse events | DTG Based Switchers to DTG/3TC | 0 | 390 |
| Total, other adverse events | DTG Based Triple Drug cART | 0 | 780 |
| Total, other adverse events | Non-DTG Based Switchers to DTG/3TC | 0 | 290 |
| Total, other adverse events | Non-DTG Based Triple Drug cART | 0 | 580 |
| Total, serious adverse events | DTG Based Switchers to DTG/3TC | 0 | 390 |
| Total, serious adverse events | DTG Based Triple Drug cART | 0 | 780 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38567196 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04707326
GET https://conductscience.org/api/trials/v1/NCT04707326/registered